Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Patient-Reported Symptom Burden Among Thyroid Cancer Survivors: Retrospective Cohort Study.
Journal: JCO clinical cancer informatics
Published: July 02, 2026
Belzutifan, A Hypoxia-Inducible Factor 2-Alpha Inhibitor, for Patients with Advanced Pheochromocytoma and Paraganglioma.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 15, 2026
A Thyroid-Cancer-Specific Utility Index: Development and Valuation of the Thyroid Cancer Quality of Life Index.
Journal: Thyroid : official journal of the American Thyroid Association
Published: February 24, 2026
Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma.
Journal: Journal of the Endocrine Society
Published: February 13, 2026
Approach to the patient with metastatic pheochromocytoma and paraganglioma: advances in systemic therapy.
Journal: The Journal of clinical endocrinology and metabolism
Published: February 12, 2026
Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study.
Journal: Endocrine pathology
Published: February 09, 2026
The evolving management of endocrine disorders induced by checkpoint inhibitors: insights from the CIITED group.
Journal: Expert review of endocrinology & metabolism
Published: November 27, 2025
Safety of biopsy in phaeochromocytoma and paraganglioma: an international, multicentre, retrospective cohort study.
Journal: The lancet. Diabetes & endocrinology
Published: November 13, 2025
Reply to the Letter to the Editor Concerning Metabolic and Pharmacological Interactions of 131 I-MIBG.
Journal: Clinical nuclear medicine
Published: October 10, 2024
SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior?
Journal: Annals of surgical oncology
Published: May 28, 2024
Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice.
Journal: Molecular and cellular endocrinology
Published: May 11, 2024
High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma.
Journal: Clinical nuclear medicine
Published: April 17, 2024
Last Updated: 09/26/2026